A ready-to-use solution for injection with no reconstitution required
† Substantiation scope note (for "first-and-only" claim): Based on review of available product labeling as of July 2026, including Zyogreen Prescribing Information and comparator ICG product labeling (IC-GREEN™, SPY AGENT® GREEN and ICG for Injection Set [KARL STORZ]). [4–7]
Solution for intravenous or interstitial use, supplied as a single-dose ampule.4
No reconstitution. No extra steps.4
Fewer preparation steps at point of care can help streamline OR workflow.1,3§
Manufacturer-prepared ready-to-use presentations have been associated with fewer observed preparation/administration errors vs traditional methods.1,2‡
A case of Zyogreen is five ampules, smaller than any of the competitive packs of Indocyanine Green. Where storage space is critical, a smaller carton makes a big difference. No diluent vials required.
A dot in the neck of the ampule can be pressed, allowing the ampule to open cleanly and without a sharp edge.
† Substantiation scope note (for "first-and-only" claim): Based on review of available product labeling as of July 2026, including Zyogreen Prescribing Information and comparator ICG product labeling (IC-GREEN™, SPY AGENT® GREEN and ICG for Injection Set [KARL STORZ]). [4–7]
‡ Evidence cited describes ready-to-use/ready-to-administer injectable formats broadly and is not specific to Zyogreen or indocyanine green clinical outcomes unless explicitly stated.
§ Outcomes reported in the cited literature vary by workflow, setting and product type; modeled evaluations are assumption-dependent.
Zyogreen is indicated for fluorescence imaging of vessels, blood flow, and tissue perfusion; fluorescence imaging of extrahepatic biliary ducts; lymphatic mapping in cervical and uterine cancer; and ophthalmic angiography, in the populations specified in the full Prescribing Information.
Zyogreen is contraindicated in patients with known hypersensitivity to indocyanine green.
Hypersensitivity reactions, including anaphylaxis, have been reported with indocyanine green. Monitor patients for hypersensitivity and have emergency equipment and trained personnel readily available.
The most common adverse reactions reported with indocyanine green products include hypersensitivity reactions. See full Prescribing Information for complete safety information.
To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the full Prescribing Information for additional Important Safety Information.
